Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: NEOTHERAPEUTICS (NEOT) (NEOTW)

No earlier versions found for this Subject.

Return to NEOTHERAPEUTICS (NEOT) (NEOTW)

This stock could be very up and coming! Today in a news release from the PRNewswire NeoTherapeutics announced that it's AIT-082 compound for treatment of Alzheimer's was cleared for clinical testing in Canada. AIT-082 has potential indications for Alzheimer's, spinal cord injury(nerve regeneration), amyotrophic lateral sclerosis, memory impairment of aging, and stroke. Alzheimer's disease is the fourth leading cause of death in the US currently.
The National Alzheimer's Assoc. has estimated the costs for the treatment and care of the current patients is about 100 billion per year.
Stroke, the third leading cause of death in the US has costs estimated at 25 billion per year.
The most interesting use is in the field of neurological disease and nerve regeneration. Where scientists have grown nerve cells across a damaged section of spinal cord and restored movement to paralyzed limbs.
In company comparisons NeoTherapeutics is trading at the lowest price/book ratio of any of the small companies in it's sector, even though it has a higher book value per share than ten of the twelve companies on the list. At 4 3/4 per share, it is trading at appx. 1.5x its book value, significantly below the avarage for the group. Neo's current market cap is also the lowest on the list at 25 million. The industry average is currently about 250 million! While Neo. is at an early stage of development, with no earnings or revenues, none of the other companies on the list have any earnings and out of the twelve other companies six have either no revenues or revenues of less than 5 million.
I believe we can agree that these type of companies are very "News Driven" and any type of news can lead to a dramatic increase in the share price. With more anticipated news to follow including rumors of US application and approval for clinical trials and rumors of a very big celeb. that is handicapped becoming involved the potential upside could be excellent!! If you need more info on this company please contact Doug MacDougall of Feinstien Partners at 1-617-577-8110.